TNFSF11 and fibrous dysplasia: We and others previously pointed to the importance of RANKL in fibrous dysplasia [7], which lead to the development of targeted therapies, first in preclinical and compassionate treatment case studies [8,9,29,30,31] and then in a clinical trial [10,11], including ongoing studies (https://clinicaltrials.gov/study/NCT05419050 [accessed 26 February 2024]).